CVR Med Corp (CRRVF: OTCQB) | CVR Announces Partnership with Dr. David J. Whellan and Thomas Jefferson University to Conduct Clinical Trials

OTC

CVR Announces Partnership with Dr. David J. Whellan and Thomas Jefferson University to Conduct Clinical Trials

Nov 30, 2016

OTC Disclosure News Service

Vancouver, BC, Canada

VANCOUVER, BC / ACCESSWIRE
/ November 30, 2016
/ CVR Medical Corp. (TSX.V:CVM) (FRANKFURT:
B3BN) (OTCQB: CRRVF)
(“CVR Medical“)
announces partnership with Dr. David J. Whellan and Thomas Jefferson University
in Philadelphia for the design and conduction of clinical trials for its
“Carotid Stenotic Scan (CSS)” device.

Dr. Whellan is the Principal Investigator of Jefferson Regional
Clinical Center for the NIH HF Network,
one of nine
centers across the United States selected to participate in a series of novel
heart failure clinical trials. Recognized as preeminent in the cardiovascular
healthcare field, his extensive clinical research has produced over 175
peer-reviewed publications on cardiovascular disease, including cardiomyopathy,
aspirin use and coronary bypass surgery. His partnership with CVR Global
signals a much-anticipated step toward providing evidence regarding the CSS for
diagnostic accuracy. With the unique capabilities present at Thomas Jefferson
University, the study will compare CSS with existing arterial diagnostic tools
across a wide range of potential subjects. CVR executive management looks
forward to working with Dr. Whellan and the institution, and expresses great
confidence that the upcoming trials will be a thorough and successful vetting
that will position the CSS strongly ahead of its market launch.

Commenting on this partnership, Dr. Whellan states, “We
have built a model here at Thomas Jefferson University to engage with companies
like CVR Global in the evaluation of novel diagnostics and treatments for a
wide variety of patients. What drew us to this project is that it’s a
technology that fits within our emphasis on innovation. We want to be a leading
organization for the evaluation of
novel therapies and
diagnostic technologies.”

For additional information on the organization, leadership, and
current news please visit the newly launched company website
www.CVRMed.com


About CVR Medical

CVR Medical is a company that is involved in an equal parts
joint venture with CVR Global Inc. (the “Joint Venture”). The Joint
Venture operates in the medical industry focused on the commercialization of a
proprietary subsonic, infrasonic, and low frequency sound wave analysis
technology and has patents to a diagnostic device designed to detect and
measure carotid arterial stenosis. CVR Medical is managed by a proven technical
team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

ON BEHALF OF THE BOARD:

(signed) “Peter Bakema”

CEO, President Director


For further information contact:

Brisco Capital Partners Corp.

Scott Koyich, President

Telephone: (403) 262-9888


This press release contains forward-looking information that
involves various risks and uncertainties regarding future events related to the
Joint Venture. Such statements are subject to risks and
uncertainties that may cause actual results, performance or developments to
differ materially from those contained in the statements and are not guarantees
of future performance of the Company. No assurance can be given that any of the
events anticipated by the forward-looking statements will occur or, if they do
occur, what benefits the Company will obtain from them. These forward-looking
statements reflect management’s current views and are based on certain
expectations, estimates and assumptions which may prove to be incorrect. A
number of risks and uncertainties could cause our actual results to differ
materially from those expressed or
implied by the forward-looking
statements, including: (1) a downturn in general economic conditions in North
America and internationally, (2) the inherent uncertainties and speculative
nature associated with commercialization of technology and the practice of
medicine, (3) a change in health regulations, (4) any number of events or
causes which may delay or cease commercialization and development of the Joint
Venture, (5) the risk that the Company or the Joint Venture does not execute
its business plan, (6) inability to retain key employees, (7) inability to
finance operations and growth, and (8) other factors beyond the Company’s
control. These forward-looking statements are made as of the date of this news
release and, except as required by law, the Company assumes no obligation to
update these forward-looking statements, or to update the reasons why actual
results differed from those projected in the forward-looking
statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR
DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE.
NEITHER
THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER
(AS THAT
TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

This release includes additional documents. Select the link(s) below to view.

NR_Partnership with Dr. D Whellan and Thomas Jefferson University_Final.pdf

Copyright © 2016 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply